Nearly two years after going live in Europe, the latest version of Abbott’s FreeStyle Libre continuous glucose monitor is ready to make its stateside debut. The FDA cleared the FreeStyle Libre 3 ...

The use of the affected product may cause serious adverse health consequences. There have been two reported injuries. Abbott announced the U.S. availability of Lingo, the company's first continuous ...

The US Food and Drug Administration has cleared Abbot's Freestyle Libre 3 system for use by people with diabetes aged 4 years and older. The new system was cleared for use for both iOS and Android ...

At least seven fires and one injury that were related to some FreeStyle Libre glucose monitor products have led the US Food and Drug Administration to issue a Class I recall, the agency's strongest, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Abbott issued a medical device correction for some ...

The new Flash Glucose Monitoring System enables patients to wear the sensor for up to 14 days compared with the existing FreeStyle Libre System that was approved for 10-day wear. Abbott announced that ...

Abbott has struck a deal to combine its FreeStyle Libre glucose sensing technology with Bigfoot Biomedical’s experimental insulin delivery device. The agreement sets Bigfoot up to start a pivotal ...

Abbott Laboratories has taken a big step in diabetes management by integrating its glucose sensor with a Tandem insulin pump, creating a hybrid closed-loop insulin delivery system. The two companies ...

ORLANDO — In a head-to-head trial comparing three currently available continuous glucose monitors (CGMs) for real-world use in diabetes, the newly approved implantable glucose monitor Eversense ...